Market closedADR
Valneva/$VALN
Valneva shares are trading lower after a law firm announced an investigation into claims on behalf of the company's investors.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Valneva
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Ticker
$VALN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
713
Website
Valneva Metrics
BasicAdvanced
$572M
-
-$0.09
1.11
-
Price and volume
Market cap
$572M
Beta
1.11
52-week high
$8.20
52-week low
$6.70
Average daily volume
25K
Financial strength
Current ratio
2.61
Quick ratio
1.776
Long term debt to equity
106.455
Total debt to equity
119.343
Interest coverage (TTM)
-3.21%
Management effectiveness
Return on assets (TTM)
-10.03%
Return on equity (TTM)
-7.91%
Valuation
Price to revenue (TTM)
5.396
Price to book
2.84
Price to tangible book (TTM)
3.28
Price to free cash flow (TTM)
-10.937
Growth
Revenue change (TTM)
10.32%
Earnings per share change (TTM)
-88.51%
3-year revenue growth (CAGR)
-21.31%
3-year earnings per share growth (CAGR)
-51.83%
Valneva News
AllArticlesVideos
$VALN
NaN%INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Accesswire·7 hours ago
$VALN
NaN%INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
Accesswire·3 days ago
$VALN
NaN%Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
GlobeNewsWire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Valneva stock?
Valneva (VALN) has a market cap of $572M as of April 04, 2025.
What is the P/E ratio for Valneva stock?
The price to earnings (P/E) ratio for Valneva (VALN) stock is 0 as of April 04, 2025.
Does Valneva stock pay dividends?
No, Valneva (VALN) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Valneva dividend payment date?
Valneva (VALN) stock does not pay dividends to its shareholders.
What is the beta indicator for Valneva?
Valneva (VALN) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
